Literature DB >> 14727050

[Continuous dialysis and hemofiltration. More than a kidney replacement method?].

M Girndt1, H Köhler.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 14727050     DOI： 10.1007/s00101-003-0593-9

Source DB:  PubMed          Journal:  Anaesthesist        ISSN： 0003-2417            Impact factor:   1.041


× No keyword cloud information.
  20 in total

Review 1.  Relevance of platelet-activating factor in inflammation and sepsis: mechanisms and kinetics of removal in extracorporeal treatments.

Authors:  C Tetta; F Mariano; J Buades; C Ronco; M L Wratten; G Camussi
Journal:  Am J Kidney Dis       Date:  1997-11       Impact factor: 8.860

2.  Haemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: a prospective randomised multicentre trial. International Multicentre Study Group.

Authors:  A Jörres; G M Gahl; C Dobis; M H Polenakovic; K Cakalaroski; B Rutkowski; E Kisielnicka; D H Krieter; K W Rumpf; C Guenther; W Gaus; J Hoegel
Journal:  Lancet       Date:  1999-10-16       Impact factor: 79.321

3.  Effect of the dialysis membrane in the treatment of patients with acute renal failure.

Authors:  R M Hakim; R L Wingard; R A Parker
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245

Review 4.  Bioincompatibility--perspectives in 1993.

Authors:  R Deppisch; E Ritz; G M Hänsch; M Schöls; E W Rauterberg
Journal:  Kidney Int Suppl       Date:  1994-01       Impact factor: 10.545

5.  Haemostatic changes in systemic inflammatory response syndrome during continuous renal replacement therapy.

Authors:  N García-Fernández; F J Lavilla; E Rocha; A Purroy
Journal:  J Nephrol       Date:  2000 Jul-Aug       Impact factor: 3.902

6.  Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration.

Authors:  P Heering; S Morgera; F J Schmitz; G Schmitz; R Willers; H P Schultheiss; B E Strauer; B Grabensee
Journal:  Intensive Care Med       Date:  1997-03       Impact factor: 17.440

7.  Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

Authors:  R V McCloskey; R C Straube; C Sanders; S M Smith; C R Smith
Journal:  Ann Intern Med       Date:  1994-07-01       Impact factor: 25.391

8.  A pilot study of coupled plasma filtration with adsorption in septic shock.

Authors:  Claudio Ronco; Alessandra Brendolan; Gerhard Lonnemann; Rinaldo Bellomo; Pasquale Piccinni; Antonio Digito; Maurizio Dan; Marco Irone; Giuseppe La Greca; Paola Inguaggiato; Umberto Maggiore; Concetta De Nitti; Mary Lou Wratten; Zaccaria Ricci; Ciro Tetta
Journal:  Crit Care Med       Date:  2002-06       Impact factor: 7.598

9.  Biocompatible membranes in acute renal failure: prospective case-controlled study.

Authors:  H Schiffl; S M Lang; A König; T Strasser; M C Haider; E Held
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

10.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

Authors:  S Okusawa; J A Gelfand; T Ikejima; R J Connolly; C A Dinarello
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.